Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Everest Medicines's Pretax Margin % or its related term are showing as below:
HKSE:01952'
s Pretax Margin % Range Over the Past 10 Years
Min: -1871428.79 Med: -670.57 Max: -35
Current: -35
HKSE:01952's Pretax Margin % is ranked better than 59.66% of 942
companies
in the Biotechnology industry
Industry Median: -89.895
vs HKSE:01952: -35.00
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Everest Medicines Pretax Margin % Related Terms
Everest Medicines Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01952 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Everest Medicines's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Medicines (HKSE:01952) has a Pretax Margin % of -27.65% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Everest Medicines and its competitors. According to the industry distribution chart, Everest Medicines ranks #380 out of 942 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Everest Medicines' Pretax Margin % too high?
Everest Medicines' current Pretax Margin % is -27.65%. Based on the distribution chart, Everest Medicines ranks #380 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Everest Medicines has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #380 out of 942 companies for Pretax Margin %. This puts Everest Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Everest Medicines and its competitors. Everest Medicines's current Pretax Margin % is -27.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$298.41, compared to a current price of HK$24.72 — trading 91.7% below its estimated fair value. The current Pretax Margin % is -27.65%. Everest Medicines' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Pretax Margin % is -27.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (HKSE:01952) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of HK$24.72 is trading 91.7% below its estimated GF Value™ of HK$298.41.
GuruFocus considers Everest Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01952:
Pretax Margin %: -27.65%
GF Value™: HK$298.41 vs. price of HK$24.72 (91.7% below fair value)
No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score
Get the complete analysis for HKSE:01952
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01952 has been successfully added to your 
